ArticleCancer discovery2018
Precision Targeted Therapy with BLU-667 for
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
208 citing papers in PubMed, 3 syntheses or guidelines pooled it, 388 citations in OpenAlex.
- The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.Investigational new drugs · 2023Pooled it
- A systematic review of salvage therapies in refractory metastatic colorectal cancer.International journal of colorectal disease · 2020Pooled it
- The Changing Face ofFrontiers in surgery · 2020Pooled it
- Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With AdvancedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.The lancet. Diabetes & endocrinology · 2021Trial
- RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases.Cell reports. Medicine · 2026Article
- Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab.ESMO gastrointestinal oncology · 2026Article
- Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.Investigational new drugs · 2026Article
- RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis.Communications biology · 2026Article
- Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- How to manage medullary thyroid carcinoma: current treatment strategies.Drugs in context · 2026Review
- Response to Selpercatinib in aLung Cancer (Auckland, N.Z.) · 2026Article
- Article
- Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report.Therapeutic advances in endocrinology and metabolism · 2026Article
- Pralsetinib-Induced Lymphocytic Colitis.ACG case reports journal · 2026Article
- Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins.Scientific reports · 2025Article
- Pathological complete response inTranslational lung cancer research · 2025Article
- Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database.International journal of clinical pharmacy · 2025Article
- Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review.Diagnostics (Basel, Switzerland) · 2025Review
- Activation of the AKT-mTOR pathway confers selpercatinib resistance in thyroid cancer cells harboring theBiochemistry and biophysics reports · 2025Article
148 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
25 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy. BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.